Sign in

You're signed outSign in or to get full access.

Geraldine Pannu

Director at Processa Pharmaceuticals
Board

About Geraldine Pannu

Geraldine Liu Pannu, age 55, has served as an independent director of Processa Pharmaceuticals since February 13, 2020; she holds a BBA from the Chinese University of Hong Kong and an MBA from Harvard Business School, and is fluent in English, Mandarin, Cantonese, and Shanghainese . The Board has determined she is “independent” under Nasdaq rules; she was born in Shanghai and grew up in Hong Kong, and brings over 25 years of investment and financial management experience .

Past Roles

OrganizationRoleTenureCommittees/Impact
GLTJ Pioneer CapitalFounding & Managing PartnerJan 2020 – PresentSpecializes in land acquisition, entitlement, and vertical development of multifamily, student, and senior housing in SF Bay Area
Golden Gate Global (GGG)Managing Director, Business DevelopmentSep 2018 – Sep 2019Led BD for leading investment fund in Bay Area
Golden Wealth Management Group (GWMG)PresidentDuring 2018–2019Affiliated with GGG; wealth management for HNW families
ChinaRock Capital ManagementCOO & Managing PartnerMar 2007 – Dec 2016Hedge and venture fund operations leadership
McKinsey & Co.; Monitor CompanyManagement ConsultantNot disclosedStrategy consulting background

External Roles

OrganizationRoleSinceExchange/TickerNotes
Royal Business BankIndependent DirectorMay 2022Nasdaq: RBBCommittee roles not disclosed

Board Governance

  • Committee assignments (2024–2025): Audit Committee member; Compensation Committee member and Chair; Nominating & Governance Committee member (Chair: Justin Yorke) .
  • Independence: Board determined Pannu is independent under Nasdaq Rule 5605(a)(2); committee independence requirements satisfied .
  • Board meeting attendance: Board met 6 times in 2023 (all directors attended); 20 times in 2024 (Pannu missed 3 meetings → 85% attendance) .
  • Committee meetings: Audit Committee met 4 times in 2024 (all attended; Baluch missed one); Compensation Committee met once in 2024 (all attended); Nominating & Governance Committee did not meet in 2024 .
Governance Element20232024
Board Meetings Held6 20
Pannu Board Attendance100% Missed 3 (85%)
Audit Committee (Meetings)4 (2023 reference provided for committee structure) 4 (all attended; Baluch missed one)
Compensation Committee (Meetings)2 (in 2023) 1 (all attended)
Nominating & Governance (Meetings)Committee active; composition disclosed 0 (no meeting)

Fixed Compensation

  • Non-employee director plan revised September 3, 2024 effective July 1, 2024: $100,000 total (cash retainer $56,000; RSUs valued at $44,000, 31,206 shares) .
  • Prior plan (March 8, 2023): $80,000 total (cash retainer $28,000; RSUs valued at $52,000, 5,069 shares) .
  • Actual 2024 compensation for Pannu: Cash fees $49,000; stock awards $44,000; total $93,000 .
  • Actual 2023 compensation for Pannu: Cash fees $28,000; stock awards $26,000; total $54,000 .
Metric20232024
Annual Cash Retainer (Plan) ($)28,000 56,000
Annual RSU Shares (Plan)5,069 31,206
Annual RSU Fair Value (Plan) ($)52,000 44,000
Pannu Fees Earned ($)28,000 49,000
Pannu Stock Awards ($)26,000 44,000
Pannu Total ($)54,000 93,000

Performance Compensation

  • Director equity awards are time-based RSUs; no performance-vesting metrics (TSR, EBITDA, ESG) disclosed for directors .
RSU Detail20232024
Grant Shares5,069 31,206
Grant Fair Value ($)52,000 44,000
VestingJune 27, 2024 Earlier of June 28, 2025 or 2025 Annual Meeting

Other Directorships & Interlocks

CompanyInterlock/Committee OverlapObservation
Royal Business Bank (RBB)Not disclosedExternal public board seat; no PCSA-related interlock disclosed
Compensation Committee InterlocksNoneProxy states no compensation committee interlocks or insider participation over prior three years

Expertise & Qualifications

  • Extensive investment and financial management experience; fund operations and capital raising across hedge, venture, and real estate funds .
  • Senior operating roles (COO/Managing Partner) at ChinaRock Capital Management; prior strategy consulting at McKinsey and Monitor .
  • Education: BBA (Chinese University of Hong Kong); MBA (Harvard Business School); multilingual (English, Mandarin, Cantonese, Shanghainese) .

Equity Ownership

Metric202320242025
Direct Shares53,113 (incl. 23,636 unvested restricted stock awards) 2,882 2,882
RSUs/Securities Within 60 DaysNot disclosed for Pannu Not disclosed for Pannu RSUs representing 36,275 shares issuable within 60 days of May 1, 2025
Pledged/Hedged SharesNot disclosedNot disclosedNot disclosed

Note: Beneficial ownership varies across years and includes equity awards; no pledging or hedging disclosures specific to Pannu were identified in the reviewed proxies .

Insider Trades & Section 16 Compliance

YearLate Form 4?Detail
2023YesLate Form 4 filed July 24, 2023 for Pannu (and others)
2024None disclosed for PannuLate filings noted for other executives; Pannu not listed among late filers

Governance Assessment

  • Strengths: Independent director; chairs the Compensation Committee; serves on Audit and Nominating & Governance, indicating broad governance engagement and oversight across pay, controls, and board composition . External public-company board experience (RBB) can enhance perspective and information flow without disclosed conflicts .
  • Alignment: Director equity grants via RSUs provide ownership exposure; 2025 disclosure shows 36,275 RSUs issuable within 60 days, supporting ongoing alignment with shareholders .
  • Attendance and engagement: 2023 board attendance was full; 2024 board attendance shows three absences out of 20 meetings (≈85%)—acceptable but below perfect, while Compensation and Audit committees had full attendance by Pannu; the Nominating & Governance Committee did not meet in 2024, which may limit formal refresh and evaluation cadence .
  • Compensation structure: Shift to higher cash retainer ($56k from $28k) and larger RSU share count in 2024 ($44k value; 31,206 shares) relative to 2023 reflects updated market approach for non-employee directors; Pannu’s reported total rose from $54k (2023) to $93k (2024) .

RED FLAGS

  • Missed three of twenty Board meetings in 2024 (≈85% attendance) .
  • Nominating & Governance Committee did not meet in 2024 (oversight cadence risk) .
  • Late Form 4 filing in 2023 (compliance process weakness, though common at microcaps) .

Overall, no related-party transactions involving Pannu were disclosed, committee independence standards are met, and her compensation is standard for non-employee directors with time-based RSUs; focus areas for ongoing monitoring include attendance consistency, nominating/governance committee activity, and Section 16 timeliness .